Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hospira Growth Aided By Drug Delivery Pump Sales, Up 19% Year-To-Date

This article was originally published in The Gray Sheet

Executive Summary

Hospira forecasts average drug delivery pump revenue growth of more than 19%, driven by increased adoption of advanced systems designed to reduce medication errors and regulatory difficulties encountered by competitor Baxter

You may also be interested in...

Baxter’s Colleague Consent Decree Enjoins Sales, Expands Obligations

Baxter signed a consent decree with FDA June 29 forbidding the sale of its widely used but malfunction-prone Colleague intravenous infusion pump until the firm complies with manufacturing quality regulations

Hospira, Baxter DEHP-Free Product Launches Signal Shift In IV Market

Two product launches announced last week highlight a shift in hospital demand away from the material that made the IV bag a reality in the 1970s

Australia Looking Into In-Vitro Self-Test Deregulation

In-vitro self-tests for influenza and sexually transmitted diseases as well as direct-to-consumer genetic tests are on the agenda for deregulation in Australia. 



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts